MedTrace Logo

HR-HPV Multi-site Opportunistic Screening in Liaoning, China

NCT03178136 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2019-01-03

No results posted yet for this study

Summary

It is universally accepted that the persistent infection of high-risk human papillomavirus(HR-HPV) is the cause of cervical intraepithelial neoplasias and cancer. Some researches indicate that the virus load may relate the extent of the disease. The objective of the study is to detect the virus load of 14 types HR-HPV among the participants, using a new HPV DNA hybrid capture technology,sequentially find the diagnostic significance of virus load of HPV.

Conditions

Sponsors & Collaborators

  • First Hospital of China Medical University

    collaborator OTHER

  • Shenyang women's and children's hostipal

    collaborator UNKNOWN

  • Dalian Medical University

    collaborator OTHER

  • The Second Affiliated Hospital of Dalian Medical University

    collaborator OTHER

  • Dandong women's and children's hostipal

    collaborator UNKNOWN

  • The First People's Hospital of Jingzhou

    collaborator OTHER

  • The second hospital of Chaoyang City

    collaborator UNKNOWN

  • Women's and children's hospital of Yingkou City

    collaborator UNKNOWN

  • Cancer hospital of Anshan City

    collaborator UNKNOWN

  • Hangzhou Dalton Biosciences,LtD

    collaborator UNKNOWN

  • Min Wang

    lead OTHER

Principal Investigators

  • Min Wang · Shengjing Hospital

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-06-19
Primary Completion
2019-06-30
Completion
2022-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03178136 on ClinicalTrials.gov